Booth Christopher M, Shepherd Frances A
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.
J Thorac Oncol. 2006 Feb;1(2):180-7.
Despite improved surgical techniques, relapse and mortality rates remain high among patients with resected non-small cell lung cancer. Numerous randomized controlled trials in the 1980s and 1990s were unable to demonstrate a consistent survival benefit for adjuvant chemotherapy. However, in the past 2 years, the results of three pivotal trials have unequivocally shown the benefit to adjuvant treatment in resected non-small cell lung cancer. In this review, we describe early adjuvant trials and highlight the recent landmark studies in this disease. The focus of ongoing and future research efforts is also discussed.
尽管手术技术有所改进，但在接受手术切除的非小细胞肺癌患者中，复发率和死亡率仍然很高。20世纪80年代和90年代的众多随机对照试验未能证明辅助化疗能带来一致的生存获益。然而，在过去两年中，三项关键试验的结果明确显示了辅助治疗对手术切除的非小细胞肺癌的益处。在这篇综述中，我们描述了早期辅助试验，并重点介绍了该疾病最近的里程碑式研究。还讨论了正在进行和未来研究工作的重点。
